<DOC>
	<DOCNO>NCT01846624</DOCNO>
	<brief_summary>This phase 2 study evaluate sequential combination decitabine midostaurin treatment newly-diagnosed acute myeloid leukemia ( AML ) old patient .</brief_summary>
	<brief_title>Decitabine Midostaurin Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>Treatment decitabine , cytidine analog , midostaurin , multi-target protein kinase inhibitor ( PKI ) , may stop growth cancer cell block enzymes need cell growth .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Newlydiagnosed acute myeloid leukemia ( AML ) per World Health Organization [ WHO ] 2008 classification [ except ( 15 ; 17 ) ] , include : De novo AML Secondary AML Secondary AML arise previouslydiagnosed myelodysplastic syndrome ( MDS ) treat deoxyribonucleic acid ( DNA ) methyltransferase inhibitor ( DNMTi ) ( ie , decitabine azacitidine ) FLT3ITD mutation confirm bone marrow aspirate Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x upper limit normal ( ULN ) Serum bilirubin ≤ 2.5 ULN Serum creatinine ≤ 1.5 mg/dL and/or creatinine clearance ≥ 50 mL/min Ejection fraction ≥ 50 % echocardiogram Unwillingness inability receive conventional chemotherapy Ability understand willingness sign write informed consent document Ability adhere study visit schedule protocol requirement Life expectancy &gt; 2 month Receiving concomitant treatment antineoplastic agent ( EXCEPTION : hydroxyurea ) . Prior treatment DNMTi therapy ( ie , decitabine azacitidine ) MDS allow Received antineoplastic treatment within 4 week prior enrollment ( EXCEPTION : hydroxyurea ) Received surgical procedure , exclude central venous catheter placement minor procedure ( eg , skin biopsy ) within 14 day study day 1 Received investigational agent within 4 week prior enrollment Previous current history myeloproliferative disease Known active central nervous system ( CNS ) malignancy Any known disease ( except carcinoma insitu ) , concurrent severe and/or uncontrolled medical condition could compromise participation study ( eg , uncontrolled diabetes ; cardiovascular disease include congestive heart failure ; myocardial infarction within 6 month poorly control hypertension ; chronic renal disease ; active uncontrolled infection ) Active opportunistic infection treatment opportunistic infection within 4 week first day study drug dose Known confirm diagnosis human immunodeficiency virus ( HIV ) infection active viral hepatitis Known impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption midostaurin History allergic reaction attribute compound similar chemical biologic composition midostaurin and/or decitabine Impaired cardiac function include follow : Screening electrocardiogram ( ECG ) correct QT interval ( QTc ) &gt; 450 msec Bradycardia define heart rate ( HR ) &lt; 50 beat per minute ( bpm ) Right bundle branch block + leave anterior hemiblock ( bifascicular block ) Patients myocardial infarction unstable angina &lt; 3 month prior start study drug Congestive heart failure ( CHF ) New York ( NY ) Heart Association class III IV Inability swallow absorb drug Other medical psychiatric illness organ dysfunction laboratory abnormality opinion investigator would compromise patient 's safety interfere data interpretation Unwillingness inability comply protocol Pregnant nursing ( lactate ) Women childbearing potential , defined woman physiologically capable become pregnant , UNLESS use highly effective method contraception dose 3 month midostaurin medication ; highly effective contraception method follow : Total abstinence , line prefer usual lifestyle subject [ periodic abstinence ( eg , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception ] Female sterilization ( surgical bilateral oophorectomy without hysterectomy ; tubal ligation least six week take study treatment ) . In case oophorectomy alone , reproductive status must confirm followup hormone level assessment Male sterilization , least 6 month prior screen ( female subject study , vasectomize male partner sole partner subject ) Combination two follow ( a+b a+c , b+c ) : Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , eg , hormone vaginal ring transdermal hormone contraception . For oral contraception , woman stable pill minimum 3 month take study treatment Placement intrauterine device ( IUD ) intrauterine system ( IUS ) Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>